Xencor (NASDAQ:XNCR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Xencor (NASDAQ:XNCR) from a strong sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other research firms have also commented on XNCR. Truist Financial lowered their price target on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Cantor Fitzgerald upped their target price on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Royal Bank Of Canada raised their price target on shares of Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $24.86.

Xencor Stock Performance

XNCR stock opened at $21.58 on Friday. The business has a 50-day simple moving average of $15.89 and a two-hundred day simple moving average of $13.44. The company has a market capitalization of $1.60 billion, a P/E ratio of -9.94 and a beta of 0.85. Xencor has a 52-week low of $6.92 and a 52-week high of $21.96.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.41) earnings per share. As a group, sell-side analysts forecast that Xencor will post -2.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

Several large investors have recently made changes to their positions in XNCR. Jefferies Financial Group Inc. lifted its holdings in Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after purchasing an additional 620,440 shares during the last quarter. Vanguard Group Inc. boosted its position in Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after purchasing an additional 61,692 shares during the period. Erste Asset Management GmbH increased its stake in shares of Xencor by 26.3% in the fourth quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock worth $7,347,000 after purchasing an additional 100,000 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Xencor by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock valued at $15,613,000 after purchasing an additional 45,599 shares during the period. Finally, BVF Inc. IL raised its position in shares of Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.